|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600117322 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-22 14:51:20 |
|
注册时间: Date of Registration: |
2026-01-22 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
前瞻性、多中心、单组目标值法评价内镜吻合夹用于内镜下软组织闭合治疗的安全性和有效性临床研究 |
|
Public title: |
A Prospective, Multicenter Clinical Study to Evaluate the Safety and Efficacy of Over-The-Scope Clip for Endoscopic Soft Tissue Closure using single-arm objective performance criteria |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
前瞻性、多中心、单组目标值法评价内镜吻合夹用于内镜下软组织闭合治疗的安全性和有效性临床研究 |
|
Scientific title: |
A Prospective, Multicenter Clinical Study to Evaluate the Safety and Efficacy of Over-The-Scope Clip for Endoscopic Soft Tissue Closure using single-arm objective performance criteria |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄晨 |
研究负责人: |
周平红 |
|
Applicant: |
Huang Chen |
Study leader: |
Zhou Pinghong |
|
申请注册联系人电话: Applicant telephone: |
+86 136 7177 8950 |
研究负责人电话:
Study leader's |
+86 21 6404 1990 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
huangchen@senscure.net |
研究负责人电子邮件: Study leader's E-mail: |
Zhou.pinghong@zs-hospital.sh.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
宁波市杭州湾新区滨海四路777号 |
研究负责人通讯地址: |
上海市徐汇区枫林路180号 |
|
Applicant address: |
777 Fourth Binhai Road, Hangzhou Bay New District, Ningbo, Zhejiang |
Study leader's address: |
No.180, Fenglin Road, Xuhui District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
宁波胜杰康生物科技有限公司 |
||
|
Applicant's institution: |
Ningbo Senscure Biotechnology Co., Ltd. |
||
|
研究负责人所在单位: |
复旦大学附属中山医院 |
||
|
Affiliation of the Leader: |
Zhongshan Hospital Fudan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2019-142R; 2019-142(2) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属中山医院伦理委员会 |
||
|
Name of the ethic committee: |
Zhongshan Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2019-12-18 00:00:00 | ||
|
伦理委员会联系人: |
牛伟新 |
||
|
Contact Name of the ethic committee: |
Niu Weixin |
||
|
伦理委员会联系地址: |
上海市徐汇区枫林路180号 |
||
|
Contact Address of the ethic committee: |
No.180, Fenglin Road, Xuhui District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6404 1990 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属中山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongshan Hospital Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市徐汇区枫林路180号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.180, Fenglin Road, Xuhui District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
宁波胜杰康生物科技有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Ningbo Senscure Biotechnology Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
上消化道穿孔/出血 |
||||||||||||||||||||||
|
Target disease: |
Upper gastrointestinal perforation/bleeding |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
评价内镜吻合夹用于内镜下软组织闭合治疗的有效性,同时确认试验器械的安全性,为产品注册上市临床应用提供依据. |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy of Over-The-Scope Clip for Endoscopic Soft Tissue Closure whilst confirming the safety of the investigational product, so as to provide evidence for registration, marketing and clinical application of the product. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄18-70周岁,性别不限; 2.受试者或者其监护人能够理解试验的目的,自愿参加并签署知情同意书,且能够按照方案要求完成随访; 3.受试者至少存在以下1种临床情况,拟在内镜下行软组织闭合治疗: a.在内镜下对上消化道肿瘤或其他病变进行切除治疗(如EFTR/ESD/EMR等)过程中产生的缺损/穿孔,需要使用金属夹闭合创面; b.各种原因导致的上消化道急性穿孔、非静脉曲张性出血或吻合口漏,计划在内镜下进行闭合治疗; |
||||||||||||||||||||||
|
Inclusion criteria |
1. age 18-70 years, male or female; 2. being able to understand the objective of the trial, willing to participate and sign the informed consent form voluntarily and complete follow-up as required in the protocol; 3. having at least one of the following clinical conditions and being scheduled for endoscopic soft tissue closure: a. Defect/perforation generated during endoscopic resection of upper gastrointestinal tumors or other lesions (e.g., EFTR/ESD/EMR, etc.), requiring use of metal clips to close the wound surface; b. Acute perforation of upper gastrointestinal tract, non-variceal bleeding or anastomotic leakage for various causes, schedued for endoscopic closure; |
||||||||||||||||||||||
|
排除标准: |
1.静脉曲张性上消化道出血者; 2.由于解剖学因素不适合进行内镜吻合夹治疗者,如内镜不能到达病变位置或病变部位、性质不适合进行吻合夹闭合治疗; 3.受试者无法耐受内镜手术或有内镜操作禁忌症者,如伴有腹膜炎或严重的心、肺、脑功能不全或多脏器功能衰竭或脓毒症等; 4.受试者有严重精神病史或意识明显障碍不能合作者; 5.受试者既往存在严重凝血功能障碍病史; 6.受试者既往存在严重的心脏病,如心肌梗死、不稳定心绞痛、心力衰竭(NYHA分级Ⅲ和Ⅳ级)等; 7.麻醉ASA分级Ⅴ级及以上; 8.合并恶性肿瘤晚期,预期寿命小于3个月; 9.育龄女性处于妊娠或哺乳期; 10.近3个月内曾参加或正在参加其他药物或医疗器械等临床研究; 11.其他经研究者评估不适合纳入本研究的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with variceal upper gastrointestinal bleeding; 2. Patients who are not suitable for Over-The-Scope Clip therapy due to anatomical factors, e.g., failure of the endoscope to reach the location or area of the lesion, the property not suitable for Over-The-Scope Clip closure; 3. Being unable to tolerate endoscopy or having contraindications for endoscopy, e.g., peritonitis or serious cardiac, pulmonary or cerebral insufficiency, multiple organ failure or sepsis; 4. Having a history of serious mental disorder or obvious consciousness disorder leading to failure of cooperation; 5. Having a previous history of serious coagulation disorder; 6. Having serious heart disease previously, e.g., myocardial infarction, unstable angina pectoris, heart failure (NYHA grade Ⅲ and Ⅳ) etc.; 7. Anesthesia ASA grade Ⅴ and above; 8. Combined with late malignant tumor, expected life span < 3 months; 9. Woman at childbearing age who is pregnant or breastfeeding; 10. Having participated in or ongoing participation in other drug or medical device clinica study in the past 3 months; 11. Other situations evaluated by investigators as unstable to be enrolled in this study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-10-28 00:00:00至 To 2021-11-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-06-08 00:00:00 至 To 2021-01-14 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
根据最终文章收录期刊要求的合法公开网络平台展示 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
According to the requirements of journal finally including the article, display on a legitimate and public online platform |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC,创达,https://edc.trialdata.cn/ |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC, Trial Data, https://edc.trialdata.cn/ |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |